Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. Francesca Palandri , Massimo Breccia , Camilla Mazzoni , Giuseppe Auteri , Elena Maria Elli , Malgorzata M Trawinska , Nicola Polverelli , Mario Tiribelli , Giulia Benevolo , Alessandra Iurlo , Alessia Tieghi , Florian H Heidel , Giovanni Caocci , Eloise Beggiato , Gianni Binotto , Francesco Cavazzini , Maurizio Miglino , Costanza Bosi , Monica Crugnola , Monica Bocchia , Bruno Martino , Novella Pugliese , Mattia Biondo , Marta Venturi , Luigi Scaffidi , Alessandro Isidori , Daniele Cattaneo , Mauro Krampera , Fabrizio Pane , Daniela Cilloni , Gianpietro Semenzato , Roberto M Lemoli , Antonio Cuneo , Elisabetta Abruzzese , Daniela Bartoletti , Simona Paglia , Nicola Vianelli , Michele Cavo , Massimiliano Bonifacio , Giuseppe A Palumbo Cancer（2023）
摘要
Cytopenic MF has a lower probability of therapeutic success with ruxolitinib as monotherapy and worse outcome. These patients should be considered for alternative therapeutic strategies.
更多 查看译文
关键词
cytopenia, myelodepletive phenotype, myelofibrosis, myeloproliferative neoplasms, ruxolitinib
AI 理解论文
溯源树
样例
